This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Quick Take: Biotech's Next Big Thing Is Earnings

NEW YORK ( TheStreet) -- Biotech has been hot this year, especially within the merger and acquisitions space. Now TheStreet's Adam Feuerstein and Gregg Greenberg are highlighting some earnings plays in the sector for next week.

Feuerstein said many large-cap biotech companies reported last week and the results were great, with earnings beats and guidance raises.

Starting things off will be Ariad Pharmaceuticals (ARIA - Get Report), which reports on Wednesday. Analysts are looking for $10 million in sales of its leukemia drug, Iclusig, while the whisper number is actually above that, in the low- to mid-teens.

What's even more important though, he says, are sales numbers for the drug that management guides for in the ensuing quarters, since prescription growth is thought to be flattening.

Dendreon (DNDN) reports earnings on Thursday. Feuerstein said the debate has been whether the company will even survive at this rate and that second half sales of Provenge will be the biggest factor.

If the outlook is high enough, it will likely quiet the talks of the company's going under.

NPS Pharmaceuticals (NPSP) will also report on Thursday. The company specializes in orphan-disease drugs, which have been on fire this year, according to Feuerstein.

He said the focus will be on the early launch of a drug that's meant to counter short bowel syndrome and that the patient tally for it at the end of the year will also be important.

-- Written by Bret Kenwell in Petoskey, Mich.

Bret Kenwell currently writes, blogs and also contributes to Robert Weinstein's Weekly Options Newsletter. Focuses on short-to-intermediate-term trading opportunities that can be exposed via options. He prefers to use debit trades on momentum setups and credit trades on support/resistance setups. He also focuses on building long-term wealth by searching for consistent, quality dividend paying companies and long-term growth companies. He considers himself the surfer, not the wave, in relation to the market and himself. He has no allegiance to either the bull side or the bear side.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ARIA $4.63 3.30%
DNDN $0.06 -6.02%
NPSP $45.97 0.02%
AAPL $94.08 0.41%
FB $103.05 1.10%


Chart of I:DJI
DOW 15,906.41 +246.23 1.57%
S&P 500 1,855.41 +26.33 1.44%
NASDAQ 4,314.81 +47.9730 1.12%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs